{
    "name": "tranexamic acid oral",
    "comment": "Rx",
    "other_names": [
        "Lysteda"
    ],
    "classes": [
        "Antifibrinolytic Agents"
    ],
    "source": "https://reference.medscape.com/drug/lysteda-tranexamic-acid-oral-999903",
    "pregnancy": {
        "common": [
            "Not indicated for use in pregnant women; there are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; tranexamic acid crosses the placenta; animal reproduction studies have not identified adverse developmental outcomes with oral administration of tranexamic acid to pregnant rats at doses up to 4 times the recommended human dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Tranexamic acid is present in the mother’s milk at a concentration of about one hundredth of the corresponding serum concentration; the amount of tranexamic acid a nursing infant would absorb is unknown; there are no adequate data on effects of tranexamic acid on breastfed infant  or on milk production; the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breast-fed child from therapy or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Women using combination hormonal contraceptives",
                "Active thromboembolic disease (eg, DVT, pulmonary embolism, or cerebral thrombosis)",
                "History of thrombosis or thromboembolism, including retinal vein or artery occlusion",
                "Intrinsic risk of thrombosis or thromboembolism (eg, thrombogenic valvular disease, thrombogenic cardiac rhythm disease, or hypercoagulopathy)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Increased risk for thrombosis when coadministered with combination oral contraceptive (see Contraindications), Factor IX complex concentrates, anti-inhibitor coagulant concentrates, or oral tretinoin",
                "Venous and arterial thrombosis or thromboembolism, as well as cases of retinal artery and retinal vein occlusions, have been reported",
                "Severe allergic reaction reported; anaphylactic shock reported with IV product",
                "May cause cerebral edema and cerebral infarction in women with subarachnoid hemorrhage",
                "Ligneous conjunctivitis reported"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dienogest/estradiol valerate",
            "description": {
                "common": "tranexamic acid oral, dienogest/estradiol valerate.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of tranexamic acid oral and combination hormonal contraceptives increases thrombotic risk."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "tranexamic acid oral, ethinylestradiol.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of tranexamic acid oral and combination hormonal contraceptives increases thrombotic risk."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mestranol",
            "description": {
                "common": "tranexamic acid oral, mestranol.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Coadministration of tranexamic acid oral and combination hormonal contraceptives increases thrombotic risk ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anti-inhibitor coagulant complex",
            "description": {
                "common": "tranexamic acid oral, anti-inhibitor coagulant complex.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may increase risk for thrombosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Factor IX",
            "description": {
                "common": "tranexamic acid oral, Factor IX.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may increase risk for thrombosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Factor IX complex",
            "description": {
                "common": "tranexamic acid oral, Factor IX complex.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may increase risk for thrombosis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "Factor IX, recombinant",
            "description": {
                "common": "tranexamic acid oral, Factor IX, recombinant.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration may increase risk for thrombosis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alteplase",
            "description": {
                "common": "tranexamic acid oral, alteplase.\nEither decreases effects of the other by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "defibrotide",
            "description": {
                "common": "tranexamic acid oral decreases effects of defibrotide by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Defibrotide may diminish effects of thrombolytic agents. Consider therapy modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "reteplase",
            "description": {
                "common": "tranexamic acid oral, reteplase.\nEither decreases effects of the other by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tenecteplase",
            "description": {
                "common": "tranexamic acid oral, tenecteplase.\nEither decreases effects of the other by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tretinoin",
            "description": {
                "common": "tranexamic acid oral, tretinoin.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration may increase procoagulant effect."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "50.4"
        },
        {
            "name": "Nasal and sinus symptoms",
            "percent": "25.4"
        },
        {
            "name": "Back pain",
            "percent": "20.7"
        },
        {
            "name": "Abdominal pain",
            "percent": "19.8"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "11.2"
        },
        {
            "name": "Arthralgia",
            "percent": "6.9"
        },
        {
            "name": "Muscle cramps and spasms",
            "percent": "5.8"
        },
        {
            "name": "Migraine",
            "percent": "6"
        },
        {
            "name": "Anemia",
            "percent": "5.6"
        },
        {
            "name": "Fatigue",
            "percent": "5.2"
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "and diarrhea",
            "percent": null
        },
        {
            "name": "Allergic skin reactions",
            "percent": null
        },
        {
            "name": "Anaphylactic shock and anaphylactoid reactions",
            "percent": null
        },
        {
            "name": "Thromboembolic events",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "DVT",
            "percent": null
        },
        {
            "name": "pulmonary embolism",
            "percent": null
        },
        {
            "name": "cerebral thrombosis",
            "percent": null
        },
        {
            "name": "acute renal cortical necrosis",
            "percent": null
        },
        {
            "name": "and central retinal artery and vein obstruction",
            "percent": null
        },
        {
            "name": "cases have been associated with concomitant use of combination hormonal contraceptives Impaired color vision and other visual disturbances",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        }
    ]
}